|32.76||+0.4200||+1.30%||Vol 770.27K||1Y Perf -47.71%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||0.96 2.93%|
|Target Price||44.50||Analyst Rating||Moderate Buy 2.20|
|Potential %||35.84||Finscreener Ranking||★★★+ 50.72|
|Insiders Trans % 3/6/12 mo.||-100/-100/-33||Value Ranking||★★★★+ 58.29|
|Insiders Value % 3/6/12 mo.||-100/-100/2||Growth Ranking||★★★★+ 62.40|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-3||Income Ranking||— -|
|Price Range Ratio 52W %||14.35||Earnings Rating||Strong Buy|
|Market Cap||1.65B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2022|
|Estimated EPS Next Report||0.63|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||746.81K|
|Avg. Monthly Volume||717.97K|
|Avg. Quarterly Volume||733.27K|
Emergent Biosolutions Inc. (NYSE: EBS) stock closed at 32.76 per share at the end of the most recent trading day (a 1.3% change compared to the prior day closing price) with a volume of 770.27K shares and market capitalization of 1.65B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2200 people. Emergent Biosolutions Inc. CEO is Robert G. Kramer.
The one-year performance of Emergent Biosolutions Inc. stock is -47.71%, while year-to-date (YTD) performance is -24.64%. EBS stock has a five-year performance of -5.45%. Its 52-week range is between 26.85 and 68.0281, which gives EBS stock a 52-week price range ratio of 14.35%
Emergent Biosolutions Inc. currently has a PE ratio of 9.80, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of 0.82, a price to cashflow ratio of 5.40, a PEG ratio of 2.32, a ROA of 5.55%, a ROC of 7.57% and a ROE of 10.17%. The company’s profit margin is 8.96%, its EBITDA margin is 21.90%, and its revenue ttm is $1.76 Billion , which makes it $34.97 revenue per share.
Of the last four earnings reports from Emergent Biosolutions Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.63 for the next earnings report. Emergent Biosolutions Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Emergent Biosolutions Inc. is Moderate Buy (2.2), with a target price of $44.5, which is +35.84% compared to the current price. The earnings rating for Emergent Biosolutions Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Emergent Biosolutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Emergent Biosolutions Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.27, ATR14 : 1.84, CCI20 : 66.15, Chaikin Money Flow : 0.04, MACD : -0.72, Money Flow Index : 61.43, ROC : 1.17, RSI : 54.72, STOCH (14,3) : 93.81, STOCH RSI : 1.00, UO : 63.92, Williams %R : -6.19), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Emergent Biosolutions Inc. in the last 12-months were: Kathryn C. Zoon (Sold 3 169 shares of value $107 891 ), Richard S. Lindahl (Buy at a value of $112 380)
Fri, 29 Apr 2022 11:25 GMT Analysts Top Healthcare Picks: Emergent Biosolutions (EBS), Viking Therapeutics (VKTX)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
This could take some time, please wait.